Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
$91.45
-$1.54(-1.52%)
At close: 4:00 PM EST
$91.45
-$1.54(-1.52%)
Day’s Range― - ―
52-Week Range$73.31 - $105.07
Previous CloseN/A
Volume3.30M
Average Volume (3M)11.40M
Market Cap
$226.98B
Enterprise Value$232.84B
Total Cash (Recent Filing)$18.21B
Total Debt (Recent Filing)$41.37B
Price to Earnings (P/E)12.1
Beta0.51
Next Earnings
Feb 03, 2026EPS Estimate
2.06Last Dividend Ex-Date
Sep 15, 2025Dividend Yield3.54%
Share Statistics
EPS (TTM)2.58
Shares Outstanding2,482,022,500
10 Day Avg. Volume11,966,775
30 Day Avg. Volume11,401,307
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda8.45
Forecast
1Y Price Target
$96.09Price Target Upside5.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentsPipeline developments such as Welireg's improvement in eRCC and the advancement of MRK-8478 to phase 3 in 2026 add potential future growth opportunities.
Undervalued StockThe stock is considered undervalued for the growth it is expected to deliver in both the near- and long-term.
Upcoming Pipeline CatalystsUpcoming pipeline catalysts include new treatments for hypercholesterolemia and HIV, which could positively impact the company's future growth.
Bears Say
Investor ApprehensionPending competitor data and loss of exclusivity for Keytruda may continue to cause investor apprehension.
Keytruda Growth ConcernsGuidance for FY25 revenue was narrowed and slightly revised down.
Uncertainty In Growth Beyond KeytrudaUncertainty around Merck's Gardasil franchise and lack of clarity around growth beyond the Keytruda LOE will continue to pressure shares.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $105.07 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $226.98B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 03, 2026 which is in 81 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 30, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.362 by $0.218.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.54%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.06.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,482,022,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.58 in its last earnings report, beating expectations of $2.362. Following the earnings report the stock price went down -0.347%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.09 (5.07% Upside)
$96.09 (5.07% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.79%
12-Months-Change
Fundamentals
Return on Equity
39.51%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Merck & Company
Merck & Company, known as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a leading global healthcare company dedicated to discovering, developing, and providing innovative medicines, vaccines, and animal health products. Founded in 1891, Merck operates in two primary sectors: Human Health, which includes prescription medicines, vaccines, biologics, and over-the-counter products, and Animal Health, which offers a range of products for livestock and companion animals. The company is renowned for its contributions to medical science, including advancements in oncology, infectious diseases, and vaccines.
MRK Company Deck
MRK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.View all MRK earnings summariesMRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$96.09
▲(5.07% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.05% Mutual Funds
6.37% Other Institutional Investors
46.95% Public Companies and Individual Investors